News

The agreements will eliminate all of InterMune’s future royalty and milestone payment obligations for pirfenidone related to the March 2002 license agreement. InterMune will also acquire exclusive worldwide

Huntington’s disease is a genetic neurodegenerative disease characterized by movement disorder, dementia and psychiatric disturbance. Steve Kanzer, chairman and CEO of Pipex, said: “Given the selective nature of

According to the Centers for Disease Control and Prevention (CDC), up to 60 million people in the US will contract influenza this year. Respiratory syncytial virus (RSV) is

Inviragen’s dengue vaccine was designed by collaborators at the Centers for Disease Control and Prevention in Fort Collins, Colorado to protect against all four of the dengue viruses.

The results of the trial will be announced after unblinding the data in the first quarter of 2008. Previously, the FDA had granted Fast Track status to Sybryx.

The new drug application (NDA) is supported by data from two Phase III clinical studies (AIR-CF1 and AIR-CF2) and interim data from an ongoing open-label extension study (AIR-CF3)

Tilidine is a prodrug, which, following oral administration, is converted to the active analgesic metabolite, nortilidine. Tilidine is indicated for the relief of acute, moderate to severe pain,

On November 2, 2007, the company closed its initial round of private equity financing since going public and obtained investment funds from accredited investors in the aggregate sum

The specific implementation of this technology is to identify and develop small molecule activators of AMP activated protein kinase to treat type 2 diabetes and metabolic syndrome. The